Cancer Center

Cancer Center

Phone Numbers

Hematology / Oncology
(803) 794-7511
Radiation Oncology
(803) 791-2575
Women's Imaging
(803) 791-2486

Breast Cancer

Our Breast Cancer Program

  • 5,000 women treated in the last 15 years.
  • One of only four centers in SC accredited by the National Program of Breast Centers.
  • Five dedicated breast cancer doctors.
(803) 791-2521

About 1 in 8 women in the United States has been diagnosed with breast cancer.

Treating Breast Cancer

Most women undergo surgery for breast cancer. Your doctor will discuss options with you and decide what’s best for your individual diagnosis.

Other Possible Treatments

Nurse Navigators

A nurse navigator will work with you throughout your treatment. She’ll help you understand your diagnosis, take care of scheduling and coordinate with doctors.

A Collaborative Team

Every Thursday, our entire team of doctors and nurses get together to review new breast cancer diagnoses and discuss treatment options.

Supportive Care

Our care is comprehensive with support for your personal challenges that goes beyond the disease.

Just a few ways we help:

New Treatments

We’ve been on the cutting edge of treatment since for 20 years and we work to bring in new techniques for our patients.

Faster, More Accurate Imaging
This PET/CT scanning system detects the spread of cancer from the breasts better than ever before and it reduces how long scanning takes.

Lymph Node Recovery

Lymphedema is a chronic swelling in the arms or legs after lymph node damage or removal, which is not uncommon in breast cancer treatment. Although there is no cure for lymphedema, we can help you reduce its effects.

Managing Lymphedema
All patients are referred to physical therapy for treatment.

To keep swelling under control, we use a combination of bandaging, exercise, skin care, and manual drainage. Our patients usually experience few significant long-term changes to their everyday lives.

The Lexington Medical Center Foundation funds treatment for patients who lack insurance, or who are underinsured.

Research Trials

We offer qualifying patients access to the latest clinical trials.

Enroll in a Clinical Trial

(803) 935-8300

WF-2202

Description
Optimizing Psychosocial Intervention for Breast Cancer-related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors. 

Open to enrollment. 

Posted By: Dr. Steven Madden

Posted Date: 5/24/2024

Location: Lexington Medical Cancer Center

NRG-CC011

Description
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Double-Blinded Controlled Trial.

A study to examine computerized training to improve concentration, learning new things, and remembering in breast cancer survivors. 

Open to enrollment. 

Posted By: Dr. Steven Madden

Posted Date: 5/23/2024

Location: Lexington Medical Cancer Center

NRG-BR008 HERO

Description
A Phase III Randomized Trial of Radiotherapy Optimization for low-risk HER2-Positive Breast Cancer.

This trial compares the recurrence-free interval (RFI) among patients with early stage, low-risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the current standard of care. 

Open to enrollment.

Posted By: Dr. Quillin Davis

Posted Date: 4/12/2024

Location: Lexington Medical Cancer Center

S2212 SCARLET

Description
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

This phase III trial compares the effects of shorter chemotherapy-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Open to enrollment.

Posted By: Dr. Steven Madden

Posted Date: 8/28/2023

Location: Lexington Medical Cancer Center

A012103

Description
Pembrolizumab vs. observation in people with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab.

Open to enrollment. 

Posted By: Dr. Steven Madden

Posted Date: 7/28/2023

Location: Lexington Medical Cancer Center

A212102

Description
Blinded Reference Set for Multicancer Early Detection Blood Tests. In this study, blood samples will be collected from patients with and without cancer to evaluate tests for early cancer detection.

Open to enrollment.

Posted By: Dr. James Wells

Posted Date: 6/23/2023

Location: Lexington Medical Cancer Center

A011801

Description
The Compassher2 Trials (Comprehensive Use Of Pathologic Response Assessment To Optimize Therapy In Her2-Positive Breast Cancer): Compassher2 Residual Disease (Rd), A Double-Blinded, Phase Iii Randomized Trial Of T-Dm1 And Placebo Compared With T-Dm1 And Tucatinib.

This trial studies how well trastuzumab emtanzine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. Giving T-DMI and tucatinib together may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. 

Open to enrollment 

Posted By: Dr. Steven Madden

Posted Date: 9/27/2019

Location: Lexington Medical Cancer Center

MA.39 Tailor RT

Description
This study tests regional radiation therapy in patients with low risk breast cancer.

Posted By: Dr. Davis

Posted Date: 9/5/2019

Location: Lexington Medical Cancer Center